Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib combined with camrelizumab for BRAF-V600 mutant conjunctival melanoma
ChiCTR2300078211Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and camrelizumab in conjunctival melanoma, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Relapse-free survival rate at 24 months. Started Jul 2022; status: recruiting.
02
Drugs
dabrafenib + trametinibcamrelizumab
03
Conditions
conjunctival melanoma
Beyond the preview
Go deeper on ChiCTR2300078211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078211.